Testicular sex cord stromal tumors represent a rare and diverse group of neoplasms that originate from the supportive elements of the testis. While germ cell tumors account for the majority of testicular malignancies, these stromal lesions constitute about 5% of cases. Most patients present with benign clinical courses. However, approximately 10% of these tumors exhibit aggressive behavior that resists standard therapies. Because they mimic other testicular masses, practitioners must understand their unique clinicopathological features to ensure effective management.

Classification of Testicular Sex Cord Stromal Tumors

Clinicians categorize these tumors into several distinct entities based on their cell of origin. Leydig cell tumors are the most frequent type, often presenting with hormonal symptoms such as gynecomastia. Sertoli cell tumors, another primary subtype, appear in various forms, including the large cell calcifying variant often linked to genetic syndromes. Other rare entities include adult and juvenile granulosa cell tumors, fibromas, and myoid gonadal stromal tumors. This classification helps specialists determine the likelihood of malignancy and the necessity for surgical intervention.

Diagnostic Challenges and Clinical Behavior

Distinguishing testicular sex cord stromal tumors from germ cell neoplasms remains a significant challenge for medical professionals. Unlike germ cell tumors, stromal tumors often present with normal serum markers like alpha-fetoprotein and beta-human chorionic gonadotropin. Consequently, imaging and histopathology become the primary tools for definitive diagnosis. Furthermore, pathologists look for specific high-risk features, such as increased mitotic activity, necrosis, and large tumor size. These indicators help predict which tumors might follow a fatal clinical course. Therefore, identifying these aggressive variants early is vital for planning surgery or surveillance.

Management Strategies for Practitioners

Management typically begins with radical orchiectomy, which serves both diagnostic and therapeutic purposes. For benign-appearing small lesions, some surgeons consider testis-sparing surgery to preserve fertility and hormonal function. In contrast, malignant cases require a multidisciplinary approach, often involving retroperitoneal lymph node dissection. Specifically, because these tumors rarely respond to conventional chemotherapy or radiation, surgery remains the cornerstone of treatment. Thus, increasing awareness among practitioners facilitates better collection of cases for targeted clinical tests and improved long-term outcomes.

What are the common symptoms of these tumors?

Most patients experience painless testicular swelling or a palpable mass. Additionally, some tumors secrete hormones, leading to signs like gynecomastia in adults or precocious puberty in children.

How do doctors differentiate them from germ cell tumors?

Clinicians utilize serum tumor markers, which are typically negative in stromal tumors. Histopathological examination after surgery provides the definitive differentiation between the two types.

Is chemotherapy effective for malignant stromal tumors?

Unfortunately, malignant variants of these tumors often show high resistance to standard chemotherapy and radiotherapy. Therefore, surgical resection remains the most effective management strategy for localized and metastatic disease.

Disclaimer: This content is for informational and educational purposes only. It is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read here. Refer to the latest local and national guidelines for clinical practice.

References

Gráczia MC et al. [Testicular sex cord stromal tumors]. Orv Hetil. 2026 May 17. doi: 10.1556/650.2026.33550. PMID: 42143686.

Lopes LF et al. Testicular sex cord-stromal tumors: a clinicopathologic study of 124 cases with focus on outcomes. Human Pathology. 2024.

EAU Guidelines on Testicular Cancer. Rare Adult Para and Testicular Tumours. European Association of Urology. 2025.